What is Attovia Therapeutics' target valuation and IPO size after upsizing, and how does it compare to its original plan?

Attovia Therapeutics is targeting a $731.5 million valuation in its upsized IPO, seeking to raise $289 million by offering 17 million shares at $17 per share — an increase from its original plan to raise up to $212.5 million via approximately 12.5 million shares priced between $15 and $17 apiece.

Who is the major financial backer involved in Attovia's IPO, and what stake will it hold?

An entity affiliated with Goldman Sachs will own about a 5.7% stake in Attovia following the IPO, as disclosed in the company's filing.

Goldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO

Aug 4, 2026

Biopharmaceutical firm Attovia Therapeutics targets a $731.5 million valuation in an upsized US IPO to raise $289 million for developing biologic therapies for immune-mediated diseases. Goldman Sachs will hold a 5.7% stake as the company lists on Nasdaq.

reuters

2026-08-04

Goldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO

Goldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO

FAQ